肺癌患者接受抗PD-1免疫治疗时接种流感疫苗不诱发免疫相关不良事件
这项队列研究纳入127例接受纳武利尤单抗治疗的肺癌患者,比较接种与未接种流感疫苗者的免疫相关不良事件(irAEs)。接种组与未接种组的irAEs发生率分别为26%和22%,率比1.20(95%CI 0.51-2.65);严重irAEs发生率分别为7%和4%,率比2.07(95%CI 0.28-15.43)。结论认为接种流感疫苗不诱发irAEs,不应因此阻止该组患者接种。
要点
- 接种流感疫苗未显著增加irAEs发生率,率比1.20(95%CI 0.51-2.65)。
- 严重irAEs率比2.07(95%CI 0.28-15.43),组间无显著差异。
- 接种与未接种组在停药、死亡、临床恶化或肿瘤缓解率上无显著差异。
核心结论
- 肺癌患者接受抗PD-1免疫治疗期间接种流感疫苗不诱发irAEs,不应阻止该组患者接种。
研究设计与样本
- 队列研究,纳入127例接受纳武利尤单抗3 mg/kg每2周治疗的肺癌患者,覆盖2015/16-2016/17两个流感季。
主要发现
- 接种组与未接种组irAEs发生率分别为26%和22%,率比1.20(95%CI 0.51-2.65)。
- 严重irAEs发生率分别为7%和4%,率比2.07(95%CI 0.28-15.43)。
- 接种组与未接种组在停药、死亡、临床恶化或肿瘤缓解率方面无显著差异。
临床怎么用
- 接受抗PD-1免疫治疗的肺癌患者可接种流感疫苗,不应因担心irAEs而推迟或取消接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Influenza vaccination is recommended in patients with cancer to reduce influenza-related complications. Recently, more immune-related adverse events (irAEs) were demonstrated in patients with lung cancer who were vaccinated with the trivalent seasonal influenza vaccine during anti-programmed death receptor 1 (PD-1) immunotherapy. Confirmation of these findings is essential before recommendations on influenza vaccination may be revoked. METHODS: In this cohort study in patients with lung cancer receiving nivolumab 3 mg/kg every 2 weeks during two influenza seasons (2015/16-2016/17), irAEs have been monitored. Incidence, timing and severity of irAEs were compared between vaccinated patients and non-vaccinated patients. FINDINGS: In a compassionate use programme, 127 patients with lung cancer had been treated with at least one dose of nivolumab during two national influenza vaccination campaigns from September until December of 2015 and 2016. Forty-two patients had received the influenza vaccine, and 85 patients were not vaccinated. Median follow-up period was 118 days (interquartile range 106-119). Mean age was 64 years (range 46-83). In vaccinated and non-vaccinated patients, the incidence of irAEs was 26% and 22%, respectively, rate ratio 1.20 (95% confidence interval [CI] 0.51-2.65). The incidence of serious irAEs was 7% and 4%, respectively, rate ratio 2.07 (95% CI 0.28-15.43). Influenza vaccination while receiving nivolumab did not result in significant differences in the rates of discontinuation, death, clinical deterioration or tumour response between the groups. INTERPRETATION: Influenza vaccination in patients with lung cancer receiving anti-PD-1 immunotherapy does not induce irAEs in our cohort. With this result, influenza vaccination should not be deterred from this group of patients.
引用
- Wijn DH, Groeneveld GH, Vollaard AM, et al. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. Eur J Cancer. 2018. PMID: 30368069. doi:10.1016/j.ejca.2018.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。